Article

Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial

2023-06-10

Abstract excerpt

In this brief report, we compare the magnitude and durability of the serologic response of one versus two doses (separated by 56 days) of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 34c55415-aaa2-5afe-b70a-8312945d60e7
DOI: 10.1101/2023.06.06.23290973

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialDOI 10.1101/2023.06.06.23290973Read

Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trialSemantic proximity Read

Three-month Antibody Persistence of a Bivalent Omicron-containing Booster Vaccine Against COVID-19Semantic proximity Read

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSemantic proximity Read

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenSemantic proximity Read

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialSemantic proximity Read

Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 studySemantic proximity Read

Immunogenicity of BA.5 Bivalent mRNA Vaccine BoostersSemantic proximity Read

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trialSemantic proximity Read

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19Semantic proximity Read

Immunogenicity of the BA.5 Bivalent mRNA Vaccine BoostersSemantic proximity Read

Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent boosterSemantic proximity Read